Use of IC tags in short-term carcinogenicity study on CB6F1 TGrasH2 mice. 2006

Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
Central Institute for Experimental Animals, Miyamae, Kawasaki, Japan.

We studied the effect of IC tags, subcutaneously implanted animal identification tools, on rasH2 mice. A 26-week short-term carcinogenicity study was performed on a total of 299 mice including 75 male and female rasH2 mice each, and 74 male and 75 female non-Tg mice from the same litter as the rasH2 mice divided into a non-IC tag group, the IC-tag group, acetone group, TPA group and MNU group (all of the animals except for those in the non-IC tag group) had IC tags implanted subcutaneously in their backs. The administration methods of the positive control drugs TPA (2.5 micro g/kg, 3 times/week, percutaneously) and MNU (75 mg/kg, single intraperitoneal injection) were based on the protocol of the ILSI/HESI international collaborative study. The results showed no differences in the tumorigenic incidence and organs developing tumors between the IC tag and non-IC tag groups in both rasH2 and non-Tg mice. In the positive control MNU group, the tumorigenic incidence and organs developing tumors were the same as the background data and no promotion of carcinogenesis was observed. In all IC tag groups including the TPA group and MNU group, a fibrous capsule was formed around the IC tags subcutaneously, but no inflammatory changes or neoplastic changes were observed. From these findings, it was concluded that the IC tag has no effect on a 26-week carcinogenicity test of rasH2 mice under the conditions of the present study.

UI MeSH Term Description Entries
D008297 Male Males
D008422 Materials Testing The testing of materials and devices, especially those used for PROSTHESES AND IMPLANTS; SUTURES; TISSUE ADHESIVES; etc., for hardness, strength, durability, safety, efficacy, and biocompatibility. Biocompatibility Testing,Biocompatible Materials Testing,Hemocompatibility Testing,Testing, Biocompatible Materials,Testing, Hemocompatible Materials,Hemocompatibility Testings,Hemocompatible Materials Testing,Materials Testing, Biocompatible,Materials Testing, Hemocompatible,Testing, Biocompatibility,Testing, Hemocompatibility,Testing, Materials,Testings, Biocompatibility
D008770 Methylnitrosourea A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties. Nitrosomethylurea,N-Methyl-N-nitrosourea,NSC-23909,N Methyl N nitrosourea,NSC 23909,NSC23909
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011905 Genes, ras Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein. Ha-ras Genes,Ki-ras Genes,N-ras Genes,c-Ha-ras Genes,c-Ki-ras Genes,c-N-ras Genes,ras Genes,v-Ha-ras Genes,v-Ki-ras Genes,H-ras Genes,H-ras Oncogenes,Ha-ras Oncogenes,K-ras Genes,K-ras Oncogenes,Ki-ras Oncogenes,N-ras Oncogenes,c-H-ras Genes,c-H-ras Proto-Oncogenes,c-Ha-ras Proto-Oncogenes,c-K-ras Genes,c-K-ras Proto-Oncogenes,c-Ki-ras Proto-Oncogenes,c-N-ras Proto-Oncogenes,ras Oncogene,v-H-ras Genes,v-H-ras Oncogenes,v-Ha-ras Oncogenes,v-K-ras Genes,v-K-ras Oncogenes,v-Ki-ras Oncogenes,Gene, Ha-ras,Gene, Ki-ras,Gene, v-Ha-ras,Gene, v-Ki-ras,Genes, Ha-ras,Genes, Ki-ras,Genes, N-ras,Genes, v-Ha-ras,Genes, v-Ki-ras,H ras Genes,H ras Oncogenes,H-ras Gene,H-ras Oncogene,Ha ras Genes,Ha ras Oncogenes,Ha-ras Gene,Ha-ras Oncogene,K ras Genes,K ras Oncogenes,K-ras Gene,K-ras Oncogene,Ki ras Genes,Ki ras Oncogenes,Ki-ras Gene,Ki-ras Oncogene,N ras Genes,N ras Oncogenes,N-ras Gene,N-ras Oncogene,c H ras Genes,c H ras Proto Oncogenes,c Ha ras Genes,c Ha ras Proto Oncogenes,c K ras Genes,c K ras Proto Oncogenes,c Ki ras Genes,c Ki ras Proto Oncogenes,c N ras Genes,c N ras Proto Oncogenes,c-H-ras Gene,c-H-ras Proto-Oncogene,c-Ha-ras Gene,c-Ha-ras Proto-Oncogene,c-K-ras Gene,c-K-ras Proto-Oncogene,c-Ki-ras Gene,c-Ki-ras Proto-Oncogene,c-N-ras Gene,c-N-ras Proto-Oncogene,ras Gene,ras Oncogenes,v H ras Genes,v H ras Oncogenes,v Ha ras Genes,v Ha ras Oncogenes,v K ras Genes,v K ras Oncogenes,v Ki ras Genes,v Ki ras Oncogenes,v-H-ras Gene,v-H-ras Oncogene,v-Ha-ras Gene,v-Ha-ras Oncogene,v-K-ras Gene,v-K-ras Oncogene,v-Ki-ras Gene,v-Ki-ras Oncogene
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D000096 Acetone A colorless liquid used as a solvent and an antiseptic. It is one of the ketone bodies produced during ketoacidosis.

Related Publications

Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
August 2002, The Journal of toxicological sciences,
Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
January 2003, Toxicologic pathology,
Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
January 2022, Toxicologic pathology,
Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
May 2001, The Journal of toxicological sciences,
Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
January 2002, Toxicologic pathology,
Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
January 1998, Toxicologic pathology,
Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
January 2017, Archives of toxicology,
Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
January 2011, Archives of toxicology,
Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
August 1978, Nature,
Koji Urano, and Syuzo Suzuki, and Kazuhiko Machida, and Nobuko Sawa, and Natsuko Eguchi, and Koji Kikuchi, and Kazumasa Fukasawa, and Fukushi Taguchi, and Toshimi Usui
January 2023, PloS one,
Copied contents to your clipboard!